The Purchase Agreement (http://www.sec.gov/Archives/edgar/data/1107332/000095013407012992/v30939exv10w1.htm) has a long list of closing opinions, including an opinion of FDA counsel (the form is not attached). And the first condition would allow the underwriter to not close if the 483 is material, assuming it was not previously disclosed to them in the OM and supplements.
5. Conditions of the Initial Purchaser’s Obligations. The obligations of the Initial Purchaser hereunder are subject to the accuracy, when made and on each Delivery Date, of the representations and warranties of the Company contained in Section 1 hereof or in certificates of any officer of the Company or the Subsidiary delivered pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder, and to each of the following additional terms and conditions:
(a) the Initial Purchaser shall not have discovered and disclosed to the Company prior to or on such Delivery Date that the Offering Memorandum or any amendment or supplement thereto contains any untrue statement of a fact which, in the reasonable opinion of counsel to the Initial Purchaser, is material or omits to state any fact which is material and necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;
(b) on each Delivery Date, Jones Day, shall have furnished to the Initial Purchaser their written opinion, as counsel to the Company, addressed to the Initial Purchaser and dated such Delivery Date, substantially in the form of Annex 1 attached hereto;
(c) on each Delivery Date, Perkins Coie, LLP, special patent counsel to the Company, shall have furnished to the Initial Purchaser their written opinion, addressed to the Initial Purchaser and dated such Delivery Date, substantially in the form of Annex 2 attached hereto;
(d) on each Delivery Date, Hyman, Phelps & McNamara, P.C. , U.S. Food and Drug Administration regulatory counsel to the Company, shall have furnished to the Initial Purchaser their written opinion, addressed to the Initial Purchaser and dated such Delivery Date, substantially in the form of Annex 3 attached hereto;
(e) Shearman & Sterling LLP, shall have furnished to the Initial Purchaser their written opinion, as counsel to the Initial Purchaser, addressed to the Initial Purchaser and dated such Delivery Date, in form and substance satisfactory to the Initial Purchaser;
(f) at the Delivery Date, there shall not have been, since the date hereof or since the respective dates as of which information is given in the Disclosure Package or the Final Offering Memorandum (exclusive of any amendments or supplements thereto subsequent to the Applicable Time), any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and the Subsidiary considered as one enterprise, whether or not arising in the ordinary course of business, and the Initial Purchaser shall have received a certificate of the Chief Executive Officer of the Company and of the Chief Financial Officer of the Company, dated as of the Delivery Date, to the effect that (i) there has been no such material adverse change, (ii) the representations and warranties in Section 1 hereof are true and correct with the same force and effect as though expressly made at and as of the Delivery Date, and (iii) the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the Delivery Date;
There is also a representation, "Compliance with Regulator Authorities" but it seems to me that would not cover the 483 situation.
(ii) Compliance with Regulatory Authorities. The clinical and pre-clinical tests conducted by or on behalf of or sponsored by the Company or the Subsidiary that are described in the documents incorporated by reference in the Final Offering Memorandum were and, if still pending, are being conducted in accordance, in all material respects, with standard medical and scientific research procedures; the descriptions in the Final Offering Memorandum of the results of such studies and tests are accurate and complete in all material respects and fairly present the data derived from such studies and tests; the Company and the Subsidiary have no knowledge of any other published studies conducted by third parties the results of which contest or contradict, and have no knowledge of any other published studies conducted by third parties that unsuccessfully attempted to replicate, the results described or referred to in the Final Offering Memorandum. Since January 1, 2003, the Company and the Subsidiary have operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the U.S. Food and Drug Administration (the “FDA”) and comparable drug regulatory agencies outside of the United States (collectively, the “Regulatory Authorities”); the Company has not received any notices or other correspondence from the Regulatory Authorities or any other governmental agency requiring the termination or suspension of any clinical or pre-clinical study or test sponsored by the Company or the Subsidiary and that is described in the Final Offering Memorandum or the results of which are referred to in the Final Offering Memorandum .
Market Data 
Markets 
AI
